Part,  Chapter, Paragraph

 1    -,     1        |        Data sources; (iii) Data description and analysis; (iv) Risk
 2    I,     2. 10.  1|      outcomes which lead to the description of groups individual prevention
 3   II,     5.  2.  3|                     5.2.3. Data description and analysis~ ~
 4   II,     5.  4.  3|                      5.4.3 Data description and analysis~ ~Comparable
 5   II,     5.  4.  8|       Diabetes Network: a brief description, Diabetes Nutrition and
 6   II,     5.  5.  1|                   5.5.1.3. Data description and analysis~ ~Prevalence,
 7   II,     5.  5.  2|                   5.5.2.3. Data description and analysis~ ~Prevalence~ ~
 8   II,     5.  5.  3|           Bulimia has a similar description in the DSMR-IV classification.
 9   II,     5.  5.  3|                 5.5.3.1.3. Data description and analysis~ ~Reviewed
10   II,     5.  5.  3|                 5.5.3.2.3. Data description and analysis~ ~Data usually
11   II,     5.  5.  3|         to be the comprehensive description of the gap between what
12   II,     5.  5.  3|         Kanner’s first clinical description with the intention to develop
13   II,     5.  5.  3|                 5.5.3.3.3. Data description and analysis~ ~Cross-sectional
14   II,     5.  5.  3|                 5.5.3.4.3. Data description and analysis~ ~In Europe,
15   II,     5.  5.  3|                 5.5.3.5.3. Data description and analysis~ ~Nearly 200
16   II,     5.  5.  3|                 5.5.3.6.3. Data description and analysis~ ~Morbidity
17   II,     5.  6.  3|                     5.6.3. Data description and analysis~ ~The major
18   II,     5.  7.  1|  Severity and Therapy~ ~ ~Stage~Description~GFR*~(mL/min per 1.73 m2 )~
19   II,     5.  7.  3|                     5.7.3. Data description and analysis~ ~Incidence~ ~
20   II,     5.  8.  3|                     5.8.3. Data description and analysis~ ~This section
21   II,     5.  9.  3|                     5.9.3. Data description and analysis~ ~Incidence
22   II,     5.  9.  6|        for achieving a complete description of asthma, focused not only
23   II,     5. 10.  2|     Union~ ~ ~ ~Code~Diagnostic description~ICD-9~693.1~Dermatitis due
24   II,     5. 10.  3|                    5.10.3. Data description and analysis~ ~Prevalence
25   II,     5. 11.  3|                    5.11.3. Data description and analysis~ ~Diseases
26   II,     5. 12.  3|                    5.12.3. Data description and analysis~ ~Graphic representations
27   II,     5. 14.  2|        major reason is that the description of periodontal condition
28   II,     5. 14.  3|                     5.14.3 Data description and analysis~ ~Dental caries~ ~
29   II,     5. 15.  3|                    5.15.3. Data description and analysis~ ~The distribution
30   II,     6.  3    |                       6.3. Data description and analysis~ ~
31   II,     8.  2.  1|                   8.2.1.3. Data description and analysis~ ~Prevalence~ ~
32   II,     8.  2.  2|                   8.2.2.3. Data Description~ ~A review and selection,
33   II,     8.  2.  3|                   8.2.3.3. Data description~ ~Prevalence of congenital
34   II,     9.  1.  2|                   9.1.2.3. Data description and analysis~ ~Prevalence
35   II,     9.  2.  3|                     9.2.3. Data description and analysis~ ~Infants and
36   II,     9.  3.  1|                   9.3.1.3. Data description and analysis~ ~Premature
37   II,     9.  3.  2|       of registration) and case description. Improvement of ascertainment
38   II,     9.  4.  3|                     9.4.3. Data description and analysis~ ~ ~By the
39   II,     9.  5.  3|                     9.5.3. Data description and analysis~ ~Health inequalities~ ~
40  III,    10.  2.  1|                10.2.1.1.3. Data description and analysis~ ~Prevalence
41  III,    10.  2.  1|                10.2.1.2.3. Data description and analysis~Alcohol consumption
42  III,    10.  2.  1|         advertising to the mere description of the product without any
43  III,    10.  2.  1|                10.2.1.3.3. Data description and analysis~ ~Overall estimates
44  III,    10.  2.  1| treatments in some regions.~The description of the drug situation presented
45  III,    10.  2.  1|                10.2.1.5.3. Data description and analysis~ ~The Burden
46  III,    10.  2.  1|                10.2.1.6.3. Data description and analysis~ ~An analysis
47  III,    10.  2.  1|                10.2.1.7.3. Data description and analysis~ ~Overweight
48  III,    10.  2.  4|      outcomes which lead to the description of groups with a significant
49  III,    10.  2.  4|                  10.2.4.3. Data description and analysis~ ~In the past
50  III,    10.  2.  5|                  10.2.5.3. Data description and analysis~ ~The Barker
51  III,    10.  3.  1|                  10.3.1.3. Data description and analysis~ ~Radon~ ~Current
52  III,    10.  3.  4|                  10.3.4.3. Data description and analysis~ ~Climatic
53  III,    10.  4.  1|                  10.4.1.3. Data description and analysis~ ~Air pollution
54  III,    10.  4.  2|                  10.4.2.3. Data description and analysis~ ~Several years
55  III,    10.  4.  4|        identify. For a detailed description of contact dermatitis associated
56  III,    10.  4.  5|     Agency (EEA) (2008).~ ~Data description and analysis~ ~ ~At present,
57  III,    10.  4.  5|       available on http ~ ~Data description and analysis~ ~Waste production~ ~
58  III,    10.  5.  1|                  10.5.1.3. Data description and analysis~ ~As human
59  III,    10.  5.  2|                  10.5.2.3. Data description and analysis.~ ~Demographic
60  III,    10.  5.  3|                   10.5.3.3 Data description and analysis~The burden
61  III,    10.  6.  1|                  10.6.1.3. Data description and analysis~ ~Data on social
62  III,    10.  6.  2|                  10.6.2.3. Data description and analysis~ ~Among the
63  III,    10.  6.  3|                  10.6.3.3. Data description and analysis~ ~Homicides:
64   IV,    11.  6.  2|                         11.6.2. Description and assessment of health
65   IV,    11.  6.  4|                         11.6.4. Description of arrangements for pooling
66   IV,    11.  6.  4|        allocation of funds, and description of the resource allocation
67   IV,    12.  2    |        permitted advertising to description of the product without any
68   IV,    12.  5    |      European Council, 2002). A description of the main activities and
69   IV,    12.  5    |        In the following a brief description of the ECHI-System is given.